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Abstract
Background
Bartonella bacilliformis is the causative agent of Carrion’s disease, a neglected illness with
mortality rates of 40–85% in the absence of treatment. The lack of a diagnostic technique to
overcome misdiagnosis and treat asymptomatic carriers is of note. This study aimed to
identify new B. bacilliformis antigenic candidates that could lead to a new diagnostic tool
able to be implemented in endemic rural areas.
Methodology/Principal Findings
Blood (n = 198) and serum (n = 177) samples were collected in northern Peru. Clinical data
were recorded. Specific 16S rRNA amplification by RT-PCR, IFA and ELISA for IgM/IgG with
whole cells as antigens was done. Western blot analysis and N-terminal amino acid sequenc-
ing detected seroreactive proteins. ELISAs for IgM/IgG for the antigenic candidates were per-
formed. Of the population 33.3% reported at least one symptom compatible with Carrion’s
disease; 25.4% (IFA), 27.1% (ELISA-IgG), 33.9% (ELISA-IgM) and 38.9% (RT-PCR) of sam-
ples were positive. Four proteins were considered potential antigenic candidates, including
two new antigenic candidates, succinyl-CoA synthetase subunit α (SCS-α) and succinyl-CoA
synthetase subunit β (SCS-β). OnWestern blot both Pap31 and SCS-α interacted with IgM,
while GroEL and SCS-β interacted with IgG. The presence of specific antibodies against the
antigenic candidates varied from 34.5% (IgG against SCS-α) to 97.2% (IgM against Pap31).
Conclusions/Significance
RT-PCR and the high levels of positivity for specific ELISAs demonstrate high levels of B.
bacilliformis exposure and asymptomatic carriers among inhabitants. The new antigens
identified might be used as a new rapid diagnostic tool to diagnose acute Carrion’s disease
and identify asymptomatic carriers.
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Author Summary
B. bacilliformis is a neglected pathogen causing Carrion’s disease, a febrile illness with two
distinct phases, the acute so-called Oroya fever that can be life-threatening, and the
chronic so-called Peruvian wart. This illness is currently limited to poor inhabitants of
Andean valleys of Ecuador, Colombia and Peru and for this reason is understudied. One
of the most significant limitations is the lack of an adequate diagnostic tool able to be
implemented in rural areas. It is imperative to unequivocally detect cases of Carrion’s dis-
ease as well as identify asymptomatic carriers who perpetuate the illness. The present
study describes the identification of 4 antigenic candidates potentially useful in the future
development of a rapid diagnostic test. Moreover, 2 of these candidates have not been
described in the literature. Additionally, four post-outbreak and one endemic community
were studied and characterized. The identification of new antigens is essential for the
development of a cheap, sensitive diagnostic tool, able to be implemented in low-income
areas.
Introduction
Bartonella bacilliformis is the etiological agent of Carrion’s disease, a neglected endemic illness
in Peru which has also been reported in Ecuador and Colombia [1]. Two well-established
phases have been described in this infection. In the acute phase, also called Oroya Fever, B.
bacilliformis infects the red blood cells which may result in severe anemia and transient immu-
nosuppression [2,3]. The absence of treatment leads to high levels of mortality (40% to 85%)
[4]. The chronic phase, ‘Verruga Peruana’ (Peruvian wart), is characterized by the development
of nodular dermal eruptions. This phase typically occurs in survivors weeks or months after
the acute febrile syndrome [5].
Clinical cure does not necessarily result in bacterial clearance. In fact, viable B. bacilliformis
have been cultured from blood samples of treated patients [6,7]. This lack of clearance together
with the development of partial immunity and the presence of continuous B. bacilliformis
exposure, means that endemic areas have a high number of individuals who are asymptomatic
carriers. Indeed, it has been described that 45% of inhabitants of endemic areas are B. bacillifor-
mis seropositive when antibodies are tested by Indirect Fluorescence Antibody (IFA) assay [8].
Studies of B. bacilliformis antigens are scarce in the literature compared with reports of
other pathogens, and a rapid diagnostic method to detect acute and/or chronic infections has
yet to be developed. To our knowledge, the first report identifying B. bacilliformis antigens was
described in 1988 by Knobloch [9]. Twenty-four protein antigens were found, including one
main antigen with 65 kDa (BB65; a heat shock protein posteriorly identified as GroEL) [9–11].
Nonetheless, BB65 never bound to Bartonella IgM but did bind to IgG antibodies after the first
two weeks, thereby demonstrating its utility to detect persisting IgG from the first to the third
year after a B. bacilliformis infection. However, only 60% of sera from Verruga Peruana patients
react with BB65 [10]. Padmalayam et al. described an immunogenic 43 kDa lipoprotein as an
antigen by screening a genomic DNA lambda library with serum from a patient in the chronic
wart phase of bartonellosis [12]. More recently, Pap31 was described to be immunologically
dominant and a good candidate for use in ELISA, but once again only one serum was used for
identification [13]. Unfortunately, none of the antigens described above have resulted in a
rapid diagnostic tool.
The objective of this study was to identify and characterize B. bacilliformis antigenic candi-
dates and take a step towards a rapid diagnostic tool able to be implemented in rural areas.
B. bacilliformis Antigenic Candidates
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Materials and Methods
Bacterial strains
The microorganisms used in this study are listed in Table 1. B. bacilliformis was cultured at
28°C on Columbia agar with 5% sheep blood for 7 days.
Study population
Blood (n = 198) and serum samples (n = 177) were collected in March 2014 in five different vil-
lages of Piura, in the north of Peru: Tunal, Guayaquiles, Los Ranchos, Mayland and Huanca-
bamba. Serum samples were collected in sodium citrate and gel SSTII advance vacutainers
(BD, Heidelberg, Germany). A B. bacilliformis outbreak occurred in 4 of these villages: between
May and November 2013 in Tunal, Guayaquiles and Mayland, and between November 2013
and March 2014 in Los Ranchos [14]. According to the national guidelines [15], all participants
had received ciprofloxacin treatment during 14 days following diagnosis during the outbreak.
All people living in the aforementioned four villages who were diagnosed (clinical symptoms
and/or thin blood smear) with acute Carrion’s disease during the previous outbreak were
invited to participate in the study. Those who agree to participate were notified by the local
health center and all samples from that village were collected on the same day. On the other
hand, Huancabamba is a long established endemic area for Carrion’s disease and the volunteers
were randomly recruited by house-to-house visits. Clinical and demographic data were
recorded in all cases. After collection the samples were kept in the appropriate refrigeration
conditions: 4°C for blood samples and sera samples were frozen. All samples were transferred
to Lima (Peru) and sera samples were also sent to Tokyo (Japan) to perform immunological
assays. In all cases transportation was performed under frozen conditions.
Ethics statement
In all the cases, signed informed consent was obtained and clinical data were anonymized. In
the case of children a parent or their guardian provided informed consent on their behalf. The
study was approved by both the Ethic Committees of the Universidad Peruana de Ciencias
Aplicadas (Lima, Peru) and the Hospital Clinic (Barcelona, Spain).
Table 1. Bacterial strains and plasmids.
Description Source or reference
Strains
B. bacilliformis CIP 57.20 –NCTC12136 Institute Pasteur
E. coli TOP10 Host strain for cloning Invitrogen
E. coli BL21Star (DE3) Host strain for gene expression Invitrogen
Plasmids
pCR4-TOPO TA-cloning vector Invitrogen
pET100D/TOPO Expression vector Invitrogen
pGroEL pET100D/TOPO containing GroEL This study
pPap31 pET100D/TOPO containing Pap31 This study
pSCS-α pET100D/TOPO containing SCS-α This study
pSCS-β pET100D/TOPO containing SCS-β This study
SCS-α: succinyl-CoA synthetase subunit α
SCS-β: succinyl-CoA synthetase subunit β.
doi:10.1371/journal.pntd.0004989.t001
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Real-Time (RT) PCR
DNA extraction was done from 200 μL blood samples with the Qiamp DNAMini Kit (Qiagen,
Hilden, Germany), according to the manufacturer’s instructions except that the final elution
volume was 100 μL. A RT-PCR was performed based on Smit et al. [16], using a BHQ quencher
probe at 125 nM and 250 nM of primers in final volume of 25 μL. RT qPCR conditions were
95°C for 15 minutes, 60 cycles of 15 seconds at 95°C and 45 seconds at 60°C and the procedure
was performed in an ABI Prism 7500 RT system and data was analyzed in the 7500 System
SDS software (Applied Biosystems, Warrington, UK). The primers and the probe used are
shown in Table 2.
IFA assay
The Chamberlin method was used with slight modifications [8]. Briefly, Vero cells were cul-
tured in sterile plates maintaining the same MOI and concentrations throughout the experi-
ment. At harvest, the Vero cell monolayer was removed with trypsin in a final volume of 10
mL. The slides were mounted with 65 μL of cells suspension per well and 20 μL 1:100 of Fluo-
rescein (FITC)-conjugated goat anti-human IgG (heavy plus light chains) (Jackson IR, Balti-
more, PA). Slides were read using a 20X objective, 10X oculars and an Olympus IX51
microscope. We used the same cut off established by Chamberlin et al., considering 1/256
serum dilution end point as a positive IFA test.
ELISA
IgM and IgG antibody levels were measured by ELISA as described by Matsuoka et al. [17]
using sonicated B. bacilliformis whole cells as antigens. Total protein concentration was quanti-
fied by the Pierce assay (Thermo Scientific, Rockford, USA). IgM were detected with rabbit
anti-human IgM (1:1000) conjugated with peroxidase and using o-Phenylenediamine (Dako,
Glostrup, Denmark) as substrate (Sigma, St. Louis, MO). IgG were detected with rabbit anti-
human IgG (1:1000) conjugated with alkaline phosphatase and using Sigma P104 phosphatase
substrate. Optical densities were measured as absorbance at 450 nm and 405/655 nm for IgM
and IgG, respectively. Each sample was analyzed in triplicate intra-plate and results were
reported as three independent ELISA experiments. The negative control, included a pool of
sera from 30 healthy donors (X0939, Dako, Glostrup, Denmark). In the absence of an
Table 2. Primers used in this study.
Sequence (5’! 3’) Ref
16S rRNA F TTGATAAGCGTGAGGTCGGAGG [16]
16S rRNA R GCAACCACACATAGTAAGCCTAA [16]
16S rRNA probe ATGTCTGCCTAGAAATCAATCATAGGCC [16]
GroEL F *CACCATGGCTGCTAAAGAAGTAAAATTT This study
GroEL R TTAGAAATCCATTCCGCCCATTCCGCC This study
Pap31 F *CACCATGAATATAAAATGTTTAGTGACA This study
Pap31 R TCAGAATTTGTAAGCAACACCAACGCG This study
SCS α F *CACCATGTCAATTCTTATC This study
SCS α R CTAACCCTTCAAGACTGAAACC This study
SCS β F *CACCATGAATATCCATGAAT This study
SCS β R TTAAGCTCCTTTTACGGCTGC This study
* CACC at the 5’ end is a sequence added to allow pET directional cloning.
doi:10.1371/journal.pntd.0004989.t002
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established cut off, evidence of infection was considered in the samples above the Finite Mix-
ture Model (FMM) cut off that provides a statistical framework for the analysis of immuno-
globulin values [18].
Western blotting
Agar-grown B. bacilliformis were lysed by sonication, separated on a 10 to 20% SDS-PAGE gel
and electrotransferred onto a PVDF membrane (GE Healthcare, Buckinghamshire, UK). The
different lanes were cut and immunoblotted with each serum for both IgG/IgM. The negative
control used in ELISA was used here.
Amino acid sequencing
Immunogenic candidate proteins were chosen according to the antibody levels obtained by
whole cell ELISA results. The membranes were stained with Coomasie brilliant blue staining
solution. Candidate proteins were directly cut out, and N-terminal amino acid sequencing was
done in APROScience (Naruto, Japan).
Amplification and cloning of antigenic candidates
Genes coding for the candidate proteins were amplified by PCR using the primers in Table 2.
Amplified products were purified and cloned in Champion pET Directional 100/D-TOPO vec-
tor (Invitrogen, Carlsbad, CA), according to the manufacturer’s instructions in order to gener-
ate Xpress-tagged-full-length versions of the candidate antigenic proteins. The DNA sequences
were verified. For the detection, E. coli lysates suspended in lysis buffer were separated on a
12.5% SDS-PAGE and immunoblotted with anti-Xpress antibody. The His6-tagged proteins
were purified using His-Bind kits (GE Healthcare, Buckinghamshire, UK).
Candidate antigens ELISA
Purified candidate proteins were used to perform ELISA and determine the reaction with sera
in study, following the same protocol mentioned previously. Here, the cut off was established
considering 3 times the standard deviation for the X0939 negative control (Dako).
Statistical analysis
Statistical analysis was performed using the Graphpad package. Significance was considered
with P<0.05. P-values were calculated using the Fisher and Mann-Whitney tests.
Results
A Carrion’s disease outbreak occurred in the Lalaquiz district (S1 Fig) between May and
November 2013. Sixty-five villages were affected, with Tunal, Guayaquiles and Mayland being
among the 10 most affected with 53.8, 19.3 and 2.56% of the cases, respectively. Meanwhile, in
Los Ranchos (in the neighboring Canchaque district) 21 cases were reported between Novem-
ber 2013 and March 2014. This outbreak was the first description of this illness in these villages.
During the outbreak, a total of 428 cases were reported, diagnosed by clinical symptoms and/or
thin blood smear. The mean age of the persons affected during the outbreak was 34 years;
52.3% of the cases were females, and 18.5% of the cases involved children up to 10 years of age.
Headache (74.7%), malaise (66%), fever (39.2%), arthralgia (31.6%), myalgia (24.4%) and pal-
lor (13%) were the most common symptoms.
We were able to collect 198 blood samples from volunteers in March 2014 and Table 3
shows the study population data. All samples collected in the 4 post-outbreak villages were
B. bacilliformis Antigenic Candidates
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from people who had been diagnosed with acute Carrion’s disease a few months earlier when
an outbreak had occurred. Despite the fact that all volunteers appeared healthy, mild symp-
toms were reported. The most common symptom described in our study population was head-
ache in 27.3% of the population, followed by 4% of people reporting fever, myalgia and
malaise. Joint pain and pallor were present in 5 and 2.5%. With regard to the endemic village, 1
(0.5%) person from the endemic area (Huancabamba) presented Verruga Peruana at the time
of sample collection. RT-PCR results showed amplification for 77 (38.9%) individuals, but it
should be taken into account that all positive samples presented very low bacteremia in blood.
Significant differences were found between the positivity results of Tunal and Guayaquiles
(P = 0.0189), Guayaquiles and Los Ranchos (P = 0.0370), Tunal and Mayland (P = 0.0006), Los
Ranchos and Mayland (P = 0.0001) and Los Ranchos and Huancabamba (P = 0.0178). Addi-
tionally, the results between Mayland and Huancabamba were almost statistically significant
(P = 0.0548) (Table 4).
Serum samples were taken from 177 (89.4%) of the individuals. Of these 45 (25.4%) had an
IFA titer 256 being considered as positive by the IFA test (Figs 1 and 2, Table 4). The IFA
results were almost significantly lower in the endemic area than in the 4 post-outbreak villages
taken together (P = 0.0575).
For the whole cell B. bacilliformis IgM ELISA, the 3 standard deviation cut off method
resulted in 95.5% of volunteers presenting levels of IgM equivalent to evidence of infection,
while with the use of FMM, the cut off was established at 0.35 (IgM) and 0.53 (IgG), with
approximately 34 and 27% of volunteers showing evidence of infection by IgM and IgG values,
respectively. Thus, in order to differentiate the most positive samples we applied the FMM cut
off.
Differences in the antibody levels between genders were not found. However, it was
observed that higher IgM levels tended to be more frequent in females (P = 0.0526) while IgG
values were significantly higher in men (P = 0.0224). On analyzing the antibody levels by locali-
ties, we saw that IgG levels were significantly higher (P<0.0001) in Huancabamba compared to
post-outbreak areas where the disease had never been described before this outbreak. This
shows the presence of a high percentage of healthy people with high levels of antibodies against
B. bacilliformis. Additionally, for IgG levels statistically significant differences (P values ranging
from<0.0001 to 0.0229) were obtained on comparing each of the post-outbreak areas with the
endemic area (Huancabamba) (Table 4). When the IgM levels were analyzed taking into con-
sideration the different age groups, we observed that young people (25 years) had signifi-
cantly higher IgM levels (P<0.0001) than adults26 years, while IgG levels only showed a
tendency to be higher in people26 years (P = 0.0753). On comparing the IgG levels of the
younger population (10 years) with each of the other age groups, we found statistically
Table 3. General data about the study population (n = 198).
Tunal Guayaquiles Los Ranchos Mayland Huancabamba Total
(n = 94) (n = 25) (n = 44) (n = 10) (n = 25)
n (%) 94 (47.5) 25 (12.6) 44 (22.2) 10 (5.1) 25 (12.6) 198 (100)
Mean age (min–max) 39.3 (1–94) 34.2 (6–67) 38.6 (5–77) 30.2 (6–73) 30.2 (9–68) 36.9 (1–94)
Male 31 (33) 8 (32) 17 (38.6) 4 (40) 16 (64) 76 (38.4)
Female 63 (67) 17 (68) 27 (61.4) 6 (60) 9 (36) 122 (61.6)
CD symptoms* 23 (24.5) 17 (68) 14 (31.8) 3 (30) 9 (36) 66 (33.3)
*The presence of at least one symptom compatible with Carrion’s disease, including fever, joint pain, headache, malaise, pallor, myalgia and warts.
doi:10.1371/journal.pntd.0004989.t003
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significant differences with all groups except people70 years (between11 -25 P = 0.0281;
26 -55 P = 0.0074;56 -70 P = 0.0246) (Fig 3).
No concordance was observed between clinical data and the positivity obtained with the
diagnostic tools used. It is interesting to note that the case of Peruvian wart was only detected
by ELISA IgG (Table 5).
Table 6 shows the concordance between each pair of techniques used. Six samples had a
positive result for at least 3 out of the 4 techniques used. This comparative analysis showed a
certain degree of dispersion and a lack of concordance (Table 6).
By doing the Western blots with the sera in the study and against whole sonicated B. bacilli-
formis we chose four proteins as possible antigenic candidates, two identified with anti-human
IgM and two with anti-human IgG (Fig 4). Amino acid sequencing revealed that the IgM can-
didates identified were Pap31 and succinyl-CoA synthetase subunit α (SCS-α) whereas for IgG
we identified GroEL and succinyl-CoA synthetase subunit β (SCS-β) (Table 7).
After cloning, expression and purification of the four antigenic candidates, we performed
ELISA for each IgM and IgG testing.
The IgM results showed a high prevalence of reactivity, from 77.4% for SCS-α to 97.2% for
Pap31. Meanwhile, the IgG reactivity in the ELISAs done for the antigens ranged from 34.5 to
SCS-α and 59.9% to SCS-β IgG (Table 8). The person with the Verruga Peruana was positive
Table 4. Positive results for each technique in the different study sites.
Tunal Guayaquiles Los Ranchos Mayland Post-outbreak
areas
Endemic area
(Huancabamba)
P1 Total
n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%)
RT-PCR 30/94
(31.9)a,c
15/25 (60)a,b 10/44
(22.7)b,d,e
9/10
(90)c,d
64/173 (37) 13/25 (52)e 0.1883 77/198
(38.9)
IFA 21/75 (28) 8/25 (32) 8/43 (18.6) 4/10 (40) 41/153 (26.8) 3/24 (12.5) 0.0575‡ 45/177
(25.4)
ELISA IgM 19/75 (25.3) 9/25 (36) 17/43 (39.5) 5/10 (50) 50/153 (32.7) 10/24 (41.7) 0.4869 60/177
(33.9)
IgG 14/75 (18.7)f 6/25 (24)g 10/43 (23.3)h 2/10 (20)i 32/153 (20.9) 16/24 (66.7)f,g,h,i 0.0001** 48/177
(27.1)
Positive for
at least one
technique†
55/75 (73.3) 23/25(92) 31/43 (72.1) 10/10
(100)
119/153 (77.8) 22/24 (91.7) 0.1715 141/177
(79.7)
†Only individuals with both blood and serum samples were considered (n = 177).
1Statistical signiﬁcance between the positivity in the 4 post-outbreak villages taken together and the positivity in the endemic area (Huancabamba).
‡IFA results were almost signiﬁcantly lower in the endemic area than in the 4 post-outbreak villages taken together (P = 0.0575).
**ELISA IgG values were signiﬁcantly higher in Huancabamba than in the 4 post-outbreak villages taken together (P = 0.0001).
The superscript letters represent the statistically signiﬁcant differences between the positivity in 2 speciﬁc areas
a P = 0.0189
b P = 0.0370
c P = 0.0006
d P = 0.0001
e P = 0.0178
f P<0.0001
g P = 0.0041
h P = 0.0007
i P = 0.0229.
The RT-PCR values between Mayland and Huancabamba were almost statistically signiﬁcant (P = 0.0548). In all cases the Fisher exact test was used.
doi:10.1371/journal.pntd.0004989.t004
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for IgG anti-GroEL, but no other specific association was observed between symptoms and
other IgM/IgG positive status.
Fig 5 shows the IgM and IgG levels for antigenic candidate ELISAS for all the study popula-
tion (Fig 5A). Moreover, Fig 5B and 5C show the IgM results of post-outbreak localities for
each antigen ELISA according to the IFA and RT-PCR results (statistically significant differ-
ences for SCS-α and SCS-β according IFA results and Pap31 according RT-PCR results). No
significant differences were found for IgG when the IFA or RT-PCR results were taken into
account. Fig 5D and 5E represent the results of the antigenic candidate ELISAs according to
the whole cell B. bacilliformis ELISA assays for the post-outbreak areas (Fig 5D) and the
endemic area (Huancabamba) (Fig 5E). It is of note that in the case of IgM, concordance
Fig 1. Distribution ofB. bacilliformis antibodies by IFA assay among the study population (n = 177).
doi:10.1371/journal.pntd.0004989.g001
Fig 2. Example of a positive IFA test. A) 20X objective and 10X oculars. B) 100X objective and 10X oculars.
doi:10.1371/journal.pntd.0004989.g002
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between the ELISAs for antigenic candidates and the ELISA for whole cell B. bacilliformis was
very high and ranged from 98.3 (59/60) to 100% (60/60). By comparing the antigenic candi-
dates ELISA results between the post-outbreak villages with the endemic area, only the IgG lev-
els of SCS-α were significantly higher in the post-outbreak areas than in Huancabamba
(P = 0.0225).
It seems that the positive samples for IgM ELISA of any of the antigenic candidates tested
show a positive correlation with the remaining candidates (P varies from<0.0001 for SCS-α /
GroEL to 0.0041 for SCS-β / GroEL). Regarding IgG ELISA of the antigenic candidates, only
GroEL did not show a significant association with the remaining antigenic candidates. None-
theless, a possible bias related to the antigenic-candidates selection process cannot be ruled out,
Fig 3. IgM and IgG antibodies in the study population. A) Overall data. Data are presented as boxplots that illustrate the medians
and the maximum and minimum. B) IgM and IgG distribution by sex; C) IgM and IgG distribution by locality. P-values obtained on
comparing the 4 post-outbreak areas with the endemic area. When comparing pairs of localities we obtained significance for IgG with
the following analysis: Guayaquiles and Huancabamba (P = 0.0001); Los Ranchos and Huancabamba (P = 0.0002); Mayland and
Huancabamba (P = 0.0201); Tunal and Huancabamba (P<0.0001). D) IgM and IgG distribution by age groups. P-values obtained
comparing the antibody levels of subjects between 25 years with 26 years. In panels B, C and D the data are presented as
boxplots that illustrate the medians and the 25th and 75th quartiles, and the whiskers represent the 10% and 90% percentiles. Outliers
are marked with circles. P-values were calculated using the Mann-Whitney test.
doi:10.1371/journal.pntd.0004989.g003
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and thus a posterior analysis using samples from different endemic areas are needed to perform
an in depth analysis.
Discussion
Currently, early diagnosis of Carrion’s disease remains an unsolved problem due to the socio-
geographical context of the endemic areas; the illness is present in poor, rural and isolated
areas with precarious access, with neither the necessary equipment nor qualified personnel to
perform molecular/immunological techniques. In endemic areas, the diagnosis is usually based
on clinical symptoms or thin blood smear, an expertise-dependent methodology with 96% of
specificity but very low sensitivity (24–36%) [19]. This problem is further enhanced by the
unspecific initial symptoms of Carrion’s disease, common to a several pathologies existing in
these areas, such as dengue and other arboviral diseases, malaria or tuberculosis [7,20]. All of
this leads to misdiagnosis of patients [20,21] and the non treatment of asymptomatic carriers,
thereby perpetuating disease transmission. The present data highlight the non-concordance
between symptomatology and antibody levels. This is a relevant fact emphasizing again the
challenges that exist in diagnosing the illness clinically. Bacterial culture is not clinically useful
due to the culture requirements and the slow bacterial growth rate [6,20]. Molecular and sero-
logic tools, like PCR or IFA are able to detect acute cases more efficiently but are very difficult
to be implemented in routine practice in remote endemic rural areas [1,8,22]. The use of sensi-
tive and specific rapid diagnostic tools is a way to overcome these limitations.
Table 5. Distribution of the positive individuals for each diagnostic technique used according to the symptoms described.
N (%)* RT ELISA_IgM ELISA_IgG IFA
n (%)* n (%)* n (%)* n (%)*
Headache 48 (27.1)** 23 (47.9) 10 (20.8) 13 (27.1) 15 (31.3)
Joint pain 10 (5.6) 3 (30.0) 2 (20.0) 2 (20.0) 4 (40.0)
Fever 8 (4.5) 4 (50.0) 2 (25.0) 3 (37.5) 4 (50.0)
Malaise 8 (4.5) 4 (50.0) 2 (25.0) 3 (37.5) 4 (50.0)
Myalgia 8 (4.5) 4 (50.0) 2 (25.0) 4 (50.0) 3 (37.5)
Pallor 5 (2.8) 4 (80.0) 2 (40.0) 1 (20.0) 4 (80.0)
Peruvian wart 1 (0.6) 0 0 1 (100.0) 0
Any symptom 60 (33.9) 27 (45.0) 13 (21.7) 17 (28.3) 18 (30.0)
* percentage in the population (considering n = 177).
** 6 more individuals presented headache but were not considered in this table because only the blood sample were collected.
doi:10.1371/journal.pntd.0004989.t005
Table 6. Concordance among the techniques used.
RT-PCR IFA ELISA IgM
N (%) N (%) N (%)
+ - + - + -
IFA + 20 (11.3) 24 (13.6)
- 53 (29.9) 80 (45.2)
ELISA IgM + 24 (13.6) 36 (20.3) 14 (7.90) 46 (26.0)
- 49 (27.7) 68 (38.4) 30 (16.9) 87 (49.2)
ELISA IgG + 19 (10.7) 29 (16.4) 9 (5.1) 39 (22.0) 19 (10.7) 29 (16.4)
- 54 (30.5) 75 (42.4) 35 (19.8) 94 (53.1) 41 (23.2) 88 (49.7)
Only individuals with both blood and serum samples were considered (n = 177).
doi:10.1371/journal.pntd.0004989.t006
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Chamberlin et al. described that 82% of acute confirmed cases and 91% of convalescents
showed a positive IFA test, while 74% of the volunteers with a positive IFA test had had Barto-
nellosis within the last year. This percentage decreased to 40% when a more distant or a non-
bartonellosis episode was reported [8]. Accordingly, the IFA positivity from the samples col-
lected in the established endemic area in our study were the lowest at 12.5%. Nonetheless, only
26.8% of the individuals from post-outbreak zones had a positive result in the IFA test. This,
Fig 4. Antigenic candidates of B. bacilliformis selected. A) SDS gel with sonicated whole cell B.
bacilliformis. B) Example of a Western blot with a positive serum by ELISA. The left panel corresponds to IgG
and the right panel to IgM.
doi:10.1371/journal.pntd.0004989.g004
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Table 7. N-terminal sequencing results.
Protein* N-terminal sequence Molecular Mass (KDa) Homologous Protein Identity** (%) Accession number Organism
A AAKEVKFGRDARERL 57.52 GroEL 100.0 CH60_BARBK Bartonella bacilliformis
57.62 GroEL 100.0 CH60_BARBA Bartonella bacilliformis
57.62 GroEL 93.3 CH60_BARHE Bartonella henselae
57.61 GroEL 93.3 CH60_BARQU Bartonella quintana
57.60 GroEL 93.3 CH60_BART1 Bartonella tribocorum
B MNIHEYQAKRLLHEY 42.74 SCS-β 100.0 SUCC_BARBK Bartonella bacilliformis
42.82 SCS-β 100.0 SUCC_BARHE Bartonella henselae
43.00 SCS-β 100.0 SUCC_BARQU Bartonella quintana
42.87 SCS-β 100.0 SUCC_BART1 Bartonella tribocorum
42.53 SCS-β 93.3 SUCC_BRUAB Brucella abortus
42.53 SCS-β 93.3 SUCC_BRUA1 Brucella abortus
42.53 SCS-β 93.3 SUCC_BRUC2 Brucella canis
42.53 SCS-β 93.3 SUCC_BRUMB Brucella melitensis
42.53 SCS-β 93.3 SUCC_BRUME Brucella melitensis
42.53 SCS-β 93.3 SUCC_BRUO2 Brucella ovis
42.53 SCS-β 93.3 SUCC_BRUSU Brucella suis
42.53 SCS-β 93.3 SUCC_BRUSI Brucella suis
42.52 SCS-β 93.3 SUCC_OCHA4 Ochrobactrum anthropi
C SILINKDTKVLVQGL 30.93 SCS-α 100.0 WP_024847155 Aminobacter spp.
30.99 SCS-α 100.0 BG36_06620 Aquamicrobium deﬂuvii
32.92 SCS-α 100.0 B9JCF2_AGRRK Agrobacterium radiobacter
30.90 SCS-α 100.0 B9JTS6_AGRVS Agrobacterium vitis
31.07 SCS-α 100.0 E6YT34_9RHIZ Bartonella spp.
30.99 SCS-α 100.0 E6YXC2_9RHIZ Bartonella spp.
30.99 SCS-α 100.0 WP_035454724 Bartonella bacilliformis
30.99 SCS-α 100.0 A1UQW0_BARBK Bartonella bacilliformis
31.01 SCS-α 100.0 E6YNR1_9RHIZ Bartonella rochalimae
30.96 SCS-α 100.0 WP_026620040 Ensifer spp.
30.90 SCS-α 100.0 A9DG17_HOEPD Hoeﬂea phototrophica
31.08 SCS-α 100.0 WP_027835951 Maritalea myrionectae
30.97 SCS-α 100.0 WP_028751285 Rhizobium leucanae
30.99 SCS-α 100.0 L0LRG5_RHITR Rhizobium tropici
30.90 SCS-α 100.0 WP_026615514 Sinorhizobium spp.
30.93 SCS-α 100.0 WP_028001748 Sinorhizobium arboris
30.87 SCS-α 100.0 G9A287_RHIFH Sinorhizobium fredii
30.97 SCS-α 100.0 I3XDY7_RHIFR Sinorhizobium fredii
30.91 SCS-α 100.0 A6UDP1_SINMW Sinorhizobium medicae
30.93 SCS-α 100.0 F7X0D4_SINMM Sinorhizobium meliloti
D ADVMIPQEISPIISA 31.70 Pap31 100.0 Q3HM50_BARBA Bartonella bacilliformis
31.16 Pap31 100.0 WP_035454931 Bartonella bacilliformis
31.61 Omp25 100.0 A1UU13_BARBK Bartonella bacilliformis
* As indicated in Fig 4.
**Only those with identity levels > 90%.
doi:10.1371/journal.pntd.0004989.t007
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together with Chamberlin’s results, suggest that IFA positivity peaks just after clinical resolu-
tion and slowly decreases thereafter. However, other factors could affect the final IFA positivity
and should be taken into account, including the B. bacilliformis strain used for its development,
and its specific levels of antigen expression as well as the subjectivity associated with the read-
ing of the slides. In fact, in a previous study developed by Chamberlin et al, differences were
observed in IFA positivity when two different B. bacilliformis strains were used [8].
Previous studies have explored the use of PCR techniques to diagnose the acute phase of
Carrion’s disease. Thus, del Valle et al [22] detected 21 acute Carrion’s disease cases analyzing
113 previously diagnosed as negative patients using a Bartonella-specific 16S rRNA based PCR.
Nonetheless, further studies showed the potential limitation of this technique to detect asymp-
tomatic carriers [23]. The use of RT-PCR has also been studied [16], 14 positive acute being
detected cases among 63 previously negative children. It has been shown that RT-PCR has a
higher sensitivity than classical PCR procedures [24], but to the best of our knowledge the use
of RT-PCR to detect asymptomatic B. bacilliformis carriers has not been performed. Nonethe-
less, the positive results observed were close to the detection limit of the technique, showing
that the bacterial burden present in the blood of asymptomatic carriers may be extremely low,
suggesting the possible presence of bacteria in specific tissues which remain apparently unde-
tected in blood over long periods of time. Although all volunteers received a 14-day course of
ciprofloxacin during the outbreak, it is noteworthy that there was still a very high number of
confirmed asymptomatic carriers by RT-PCR. This suggests that the short time elapsed since
the outbreak might have favored the high number of positive samples by RT-PCR. Despite a
case in which the duration of asymptomatic bacteremia was up to 3 years [25], there is a lack of
in depth studies about bacteremia in asymptomatic carriers. In any case all these results high-
light the enormous relevance of the need for techniques which may be implemented in
endemic areas to detect asymptomatic carriers in order to adequately control and possibly
eradicate this illness.
ELISA data showed high levels of antibodies against B. bacilliformis, which was expected
because an outbreak had occurred several months earlier in 4 out of 5 of the villages analyzed.
It is known that inhabitants of endemic areas develop partial immunity due to exposure to B.
bacilliformis [5]. Accordingly, the inhabitants from the long established endemic infected area
showed significantly higher IgG levels when compared with the other 4 non-endemic villages
together or with each of the post-outbreak villages. Similarly, IgM and IgG levels were age-
dependent suggesting the development of partial immunity throughout life. The IgM levels
were significantly higher when comparing individuals25 years-old with adults26 years.
Moreover, the IgG levels were significantly lower for the age group10 years-old when com-
pared with each of the age groups of adult population (11 -25;26 -55 and56 -<70)
with the exception of individuals70 years. Regarding the differences in the antibody levels by
gender, the IgG levels were higher in men probably because men often move to the neighboring
Table 8. Positive prevalence for the antigenic candidate ELISAs.
SCS-α* Pap31 SCS-β* GroEL
N (%) N (%) N (%) N (%)
IgM 137 (77.4) 172 (97.2) 168 (94.9) 138 (78.0)
IgG 61 (34.5) 104 (58.8) 106 (59.9) 70 (39.5)
*Succinyl-CoA synthetase. Cut offs considered: SCS-α (IgM) = 0.076; SCS-α (IgG) = 0.130; Pap31 (IgM) =
0.088; Pap31 (IgG) = 0.212; SCS-β (IgM) = 0.056; SCS-β (IgG) = 0.107; GroEL (IgM) = 0.093; GroEL (IgG) =
0.400
doi:10.1371/journal.pntd.0004989.t008
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endemic areas such as Cajamarca department (San Ignacio area) to work in the coffee bean
harvesting. The relation between coffee plantations and the presence of Lutzomyia spp. has
already been reported [26].
The presence of antibodies and the blood carriage of B. bacilliformis open the door to differ-
ent possibilities such as the bacterial evasion of the host immune system by changes in the
expression of bacterial epitopes which may correlate with decreased ability to invade erythro-
cytes and facilitate bacterial trapping in other tissues.
Fig 5. IgM and IgG levels for antigenic candidate ELISAs. A) Overall IgM and IgG data for the study
population. Data are presented as boxplots that illustrate the medians and the 1 and 99% percentiles.
Outliers are marked with circles. B) IgM ELISA results of post-outbreak localities for SCS-α, Pap31, SCS-β
and GroEL according to IFA results. C) IgM ELISA results of post-outbreak localities for SCS-α, Pap31, SCS-
β and GroEL according to RT-PCR results. D) IgM and IgG ELISA result of post-outbreak population for SCS-
α, Pap31, SCS-β and GroEL taking into account the whole cell B. bacilliformis ELISA assay. E) IgM and IgG
ELISA result for the endemic area (Huancabamba) for SCS-α, Pap31, SCS-β and GroEL according to the
whole cell B. bacilliformis ELISA assay. For B, C, D and E data are presented as boxplots that illustrate the
medians and the 25th and 75th quartiles, and the whiskers represent the 1% and 99% percentiles. Outliers
are marked with circles. P-values were calculated using the Mann-Whitney test.
doi:10.1371/journal.pntd.0004989.g005
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In the present study we have identified four potential antigenic candidates, two of which
have previously been reported in the literature, GroEL and Pap31 [9,10,13], while the remain-
ing two are described for the first time. These new antigenic candidates, SCS-α and SCS-β are
involved in the tricarboxylic acid cycle, an important cytosolic metabolic pathway. Indeed, sub-
unit α has been described as an immunogenic protein of Brucella melitensis [27], and the β sub-
unit was recently reported in Bartonella henselae pathogenesis [28].
Pap31 or Hemin-binding protein A has shown to be a good candidate in the ELISA tech-
nique and is highly expressed in B. bacillifomis cultures [13]. Furthermore, Pap31 is an outer
membrane protein that seems to be good candidate for the development of serodiagnostic tools
for Bartonella infections, as proposed for Bartonella quintana infections [17].
Knobloch et al. [10] described that GroEL, a heat shock protein, never bound to Bartonella
IgM antibodies, suggesting that GroEL may be a good antigenic candidate for the chronic
phase. Similarly, in the present study GroEL was identified as reactive with IgG. However, we
were also able to detect IgM anti-GroEL. Differences in the time elapsed from the infection and
the sample collection may explain this finding. GroEL is present in the outer and inner mem-
branes of B. bacilliformis, having also been detected in B. bacilliformis supernatants. Its pres-
ence is correlated with mitogenic activity against human vascular endothelial cells which leads
to the development of verrucous lesions [29]. This mitogenic activity is inhibited in vitro by the
presence of specific anti-GroEL antibodies, suggesting the protective role of specific IgG in
asymptomatic carriers. Indeed, the presence of specific IgG anti-GroEL was observed in the
volunteer presenting a Verruga Peruana. GroEL has also been described as a good candidate
for vaccine production and the development of diagnostic kits for Brucella melitensis [30].
The strong correlation between the positive results for IgM ELISAs anti-B. bacilliformis
whole cell and positive results for antigenic candidates, suggests that the antigens can be used
indistinctly in a rapid diagnostic test. These are preliminary results and more studies should be
done to characterize these B. bacilliformis antigens.
To the best of our knowledge, to date only 5 antigenic candidates of B. bacilliformis have
been described in the literature. In this study we have identified 2 new antigens of B. bacillifor-
mis. These kind of antigens are of special relevance in the development of new, easy and cheap
rapid diagnostic tools, able to be implemented in remote rural areas without the need for spe-
cific expertise. The diagnosis and treatment of both patients and asymptomatic carriers, who
continue to perpetuate the illness, is crucial to reduce the burden of this disease. Therefore,
studies characterizing antigens expressed during B. bacilliformis infection are fundamental to
elucidate the pathogenesis of this disease and may be useful for the development of a rapid
diagnostic tool, absolutely necessary to advance towards Carrion’s disease eradication.
Supporting Information
S1 Fig. The figure shows the geographical localization (district, province and department)
of the study area. Three of the villages (Tunal, Guayaquiles and Mayland) are located within
the Lalaquiz district, while Los Ranchos is in Canchaque district, and Huancabamba is in the
homonymous district.
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